Comparative measurements of pressurised metered dose inhaler (pMDI) stem displacement

Paul M. Young; Robert Price

doi:10.1080/03639040701484205

Comparative measurements of pressurised metered dose inhaler (pMDI) stem displacement

Paul M. Young, Robert Price

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

A technique was developed to enable direct measurement of a pressurised metered dose inhaler actuation cycle. Three commercially available 250 μg.dose−1 beclomethasone diproprianate formulations were chosen for analysis; Becloforte (Glaxosmithkline, Sussex), Clenil Forte (Chiesi, Parma, Italy), and BDP-Modulite (Chiesi-Glaxosmithkline). The compression cycle of each device was analyzed and the point of drug actuation (force at which drug was released as an aerosol) was determined. Quantitative analysis of three devices from each product suggested no significant variation in inter-batch actuation force (ANOVA, p < 0.05) (N = 3). Interestingly, a significant variation between product type actuation force was observed (ANOVA, p < 0.05) (N = 3). Actuation forces ranged from 22.33 N ± 1.44 N for Becloforte to 31.12 N ± 2.73 N for Clenilforte. In general, such observations suggested a maximum difference of 8.7 N between the two extremes, equivalent to a 39% increase in force required to receive a dose.

Original language	English
Pages (from-to)	90-94
Number of pages	5
Journal	Drug Development and Industrial Pharmacy
Volume	34
Issue number	1
DOIs	https://doi.org/10.1080/03639040701484205
Publication status	Published - 2008
Externally published	Yes

Keywords

pMDI
CFC
HFA
compression force

Access to Document

10.1080/03639040701484205

Cite this

@article{3d74d6d139654d01a1503ac9856f7f65,

title = "Comparative measurements of pressurised metered dose inhaler (pMDI) stem displacement",

abstract = "A technique was developed to enable direct measurement of a pressurised metered dose inhaler actuation cycle. Three commercially available 250 μg.dose−1 beclomethasone diproprianate formulations were chosen for analysis; Becloforte (Glaxosmithkline, Sussex), Clenil Forte (Chiesi, Parma, Italy), and BDP-Modulite (Chiesi-Glaxosmithkline). The compression cycle of each device was analyzed and the point of drug actuation (force at which drug was released as an aerosol) was determined. Quantitative analysis of three devices from each product suggested no significant variation in inter-batch actuation force (ANOVA, p < 0.05) (N = 3). Interestingly, a significant variation between product type actuation force was observed (ANOVA, p < 0.05) (N = 3). Actuation forces ranged from 22.33 N ± 1.44 N for Becloforte to 31.12 N ± 2.73 N for Clenilforte. In general, such observations suggested a maximum difference of 8.7 N between the two extremes, equivalent to a 39% increase in force required to receive a dose.",

keywords = "pMDI, CFC, HFA, compression force",

author = "Young, {Paul M.} and Robert Price",

year = "2008",

doi = "10.1080/03639040701484205",

language = "English",

volume = "34",

pages = "90--94",

journal = "Drug Development and Industrial Pharmacy",

issn = "0363-9045",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Comparative measurements of pressurised metered dose inhaler (pMDI) stem displacement

AU - Young, Paul M.

AU - Price, Robert

PY - 2008

Y1 - 2008

N2 - A technique was developed to enable direct measurement of a pressurised metered dose inhaler actuation cycle. Three commercially available 250 μg.dose−1 beclomethasone diproprianate formulations were chosen for analysis; Becloforte (Glaxosmithkline, Sussex), Clenil Forte (Chiesi, Parma, Italy), and BDP-Modulite (Chiesi-Glaxosmithkline). The compression cycle of each device was analyzed and the point of drug actuation (force at which drug was released as an aerosol) was determined. Quantitative analysis of three devices from each product suggested no significant variation in inter-batch actuation force (ANOVA, p < 0.05) (N = 3). Interestingly, a significant variation between product type actuation force was observed (ANOVA, p < 0.05) (N = 3). Actuation forces ranged from 22.33 N ± 1.44 N for Becloforte to 31.12 N ± 2.73 N for Clenilforte. In general, such observations suggested a maximum difference of 8.7 N between the two extremes, equivalent to a 39% increase in force required to receive a dose.

AB - A technique was developed to enable direct measurement of a pressurised metered dose inhaler actuation cycle. Three commercially available 250 μg.dose−1 beclomethasone diproprianate formulations were chosen for analysis; Becloforte (Glaxosmithkline, Sussex), Clenil Forte (Chiesi, Parma, Italy), and BDP-Modulite (Chiesi-Glaxosmithkline). The compression cycle of each device was analyzed and the point of drug actuation (force at which drug was released as an aerosol) was determined. Quantitative analysis of three devices from each product suggested no significant variation in inter-batch actuation force (ANOVA, p < 0.05) (N = 3). Interestingly, a significant variation between product type actuation force was observed (ANOVA, p < 0.05) (N = 3). Actuation forces ranged from 22.33 N ± 1.44 N for Becloforte to 31.12 N ± 2.73 N for Clenilforte. In general, such observations suggested a maximum difference of 8.7 N between the two extremes, equivalent to a 39% increase in force required to receive a dose.

KW - pMDI

KW - CFC

KW - HFA

KW - compression force

UR - http://www.scopus.com/inward/record.url?scp=38549109397&partnerID=8YFLogxK

U2 - 10.1080/03639040701484205

DO - 10.1080/03639040701484205

M3 - Article

C2 - 18214760

SN - 0363-9045

VL - 34

SP - 90

EP - 94

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

IS - 1

ER -

Comparative measurements of pressurised metered dose inhaler (pMDI) stem displacement

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this